Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders

a technology of wnt-mediated disorders and antagonists, which is applied in the direction of growth factor/regulator receptors, drug compositions, peptides, etc., can solve the problems of tumor formation, cell change, tumor development,

Inactive Publication Date: 2010-10-21
GENENTECH INC
View PDF13 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides Wnt antagonists that can be used to diagnose and treat Wnt-mediated disorders and inhibit cellular Wnt signaling. These antagonists consist of a Frizzled domain component and an immunoglobulin Fc domain. The Frizzled domain component is a polypeptide derived from a Frizzled protein, while the Fc domain is derived from an immunoglobulin. The Wnt antagonists can be used as a method of diagnosis and treatment by administering them to patients with Wnt-mediated disorders. The invention also provides methods for making and using the Wnt antagonists.

Problems solved by technology

The result of such viral integration was unregulated expression of Int-1 resulting in the formation of tumors.
The subsequent upregulation in transcription of these target genes leads to changes in the cell, and continuous, unregulated expression of such target genes results in tumor development.
However, while such Frizzled fragments did exhibit binding to Wnt ligand, such fragments are unsuitable for therapeutics because of their rapid degradation in vivo.
However, prior to the present invention, attempts at creating a soluble Frizzled receptor-Fc fusion therapeutic were not successful.
Additionally, while the creation of Fc fusions is generally known as one technique to improve the in vivo stability of the resulting construct, the creation of effective therapeutic Fc constructs can be difficult owing to a number of problems, including improper protein folding of the new protein construct and steric hindrance of the fusion construct to the target.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
  • Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
  • Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

General Protocols

Mammalian Cell Culture.

[0325]Human kidney epithelial (HEK) 293 cells (ATCC #CRL-1573), human ovarian PA1 cells (ATCC #CRL-1572) were grown in 50 / 50 Dulbecco modified Eagle high glucose medium, Ham's F12 which has been supplemented with 10% fetal bovine serum. Human teratoma derived NTer2 (ATCC #CRL-1973) and Tera2 (ATCC#HTB-106) cells were maintained in McCoy's medium supplemented with 15% fetal bovine serum and NCCIT cells (ATCC #CRL-2073) were maintained in RPMI supplemented with 10% fetal bovine serum. All cell lines were further supplemented with 2 mM glutamine, and 1% penicillin-streptomycin at 37° C. in 5% CO2.

Transfection and Luciferase Assays

[0326]In preparation for transfection, (1) 500,000 HEK293 and (2) 100,000 PA1 cells (ATCC #CRL-1572), NCCIT, NTera2 or Tera2 cells were plated into each well of a 12-well dish (Nuc) 24 hours before transfections. Cells were transfected with 0.375 μg TOPglow (Upstate, Cat #21-204), 0.05 mg LEF1, 0.01 mg SV40 RL with Fugen...

example 2

Construction of Frz-Fc Chimeric Molecules

Cloning and Expression

Frz8(173)-Fc and Frz8(156)-Fc

[0327]FIGS. 4A and B show the sequences of the Frz8 (156)-Fc and Frz8 (173)-Fc chimeric constructs. FIG. 4A shows the longer Frz8(173) sequence. Shown in gray (i.e., first 24 N-terminal amino acid residues) is the leader signal sequence. Shown in underline (i.e., residues 25-27) are alanine residues that may be present or absent in the mature protein. Shown in boxed text (i.e., residues 157-173) are the additional sequences of the Frz8 receptors that distinguish the longer Frz8 (173) from the shorter Frz8(156) chimeric constructs. Shown in bold (i.e., residues 174-182) is the linker sequence, while the sequence in italics (i.e., residues 183-409) is the Fc region. FIG. 4B shows the shorter Frz (156) minimal CRD (ECD) domain sequence. In gray (i.e., first 24 N-terminal amino acid residues) is the leader signal sequence. Shown in underline (i.e., residues 25-27) are alanine residues that may be...

example 3

Serum Stability of Frz8-Fc Chimeric Molecules

[0334]Initial studies of the serum stability of the Frz8(173)-Fc chimeric constructs indicated that the construct had a limited in vivo half-life. The in vivo instability was likely due to the presence of protease cleavage sites in the EC domain (ECD) of the Frizzled receptor component. The Frz8(156)-Fc construct described in Example 2 exhibited increased serum stability over the Frz8(173)-Fc. Athymic nude mice were injected i.v. with 10 mg / kg of either Frz8(173)-Fc or Frz8(156)-Fc. Serum was collected at specified time points and analyzed for total and active protein. FIG. 11A shows an immunoblot for human Fc used to detect the protein present in 1 μL of serum and compared with 25 μg of the respective purified protein (P). Frz8(156)-Fc was detectable in serum 72 h after administration, whereas Frz8(173)-Fc was not detectable beyond 30 minutes.

[0335]The activity of Frz8(156)-Fc and Frz8(173)-Fc in the collected serum was assayed by measur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 11 / 851,596 filed Sep. 7, 2007 which in turn claims priority to to U.S. Provisional Application Ser. No. 60 / 825,063, filed Sep. 8, 2006, and U.S. Provisional Application Ser. No. 60 / 951,175, filed Jul. 20, 2007, both of which are incorporated by reference in their entirety herein.FIELD OF THE INVENTION[0002]The present invention relates generally to the regulation of cell growth. More specifically, the present invention relates to inhibitors of the Wnt pathway as well as to their use in the diagnosis and treatment of disorders characterized by the activation of Wnt pathway signaling, as well as to the modulation of cellular events mediated by Wnt pathway signaling.BACKGROUND OF THE INVENTION[0003]The Wnt signaling pathway's association with carcinogenesis began as a result of early observations and experiments in certain murine mammary tumors. Wnt-1 proto-oncogene (Int-1) was originally identifi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07K16/00A61P35/00C12N5/07
CPCA61K38/00G01N2333/71C07K14/71C07K14/4702A61P35/00A61P35/04A61P43/00Y02A50/30A61K38/17C12N15/62C07K14/705G01N33/50
Inventor ERNST, JAMES A.POLAKIS, PAULRUBINFELD, BONNEEDEALMEIDA, VENITA I.
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com